drugset / Trial / NCT00940953

Compare Captisol-Enabled (CE) Budesonide + Azelastine Nasal Solution and Rhinocort Aqua + Astelin in an Environmental Exposure Chamber (EEC) Study of Allergic Rhinitis

NCT00940953

Phase 2 Completed 108 enrolled Ligand Pharmaceuticals
RandomizedCrossoverTriple-blindTreatment

Summary

The primary objective of this study was to compare Placebo to Captisol-Enabled Budesonide + Azelastine in a single spray and two separate sprays (Budesonide + Azelastine) in patients with Seasonal Allergic Rhinitis exposed to controlled ragweed pollen.

Timeline

Start
2008-02
Primary completion
2008-05
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Azelastine Small molecule Intranasal
Comparator Budesonide Small molecule Intranasal